CN1174991C - 克拉霉素的o型结晶 - Google Patents

克拉霉素的o型结晶 Download PDF

Info

Publication number
CN1174991C
CN1174991C CNB971814325A CN97181432A CN1174991C CN 1174991 C CN1174991 C CN 1174991C CN B971814325 A CNB971814325 A CN B971814325A CN 97181432 A CN97181432 A CN 97181432A CN 1174991 C CN1174991 C CN 1174991C
Authority
CN
China
Prior art keywords
erythromycin
type
solvate
powder
peak
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB971814325A
Other languages
English (en)
Chinese (zh)
Other versions
CN1244869A (zh
Inventor
Sg
S·G·斯潘顿
R·F·亨赖
D·A·里莱
刘日华
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott GmbH and Co KG
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25136084&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1174991(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of CN1244869A publication Critical patent/CN1244869A/zh
Application granted granted Critical
Publication of CN1174991C publication Critical patent/CN1174991C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
CNB971814325A 1997-01-17 1997-12-19 克拉霉素的o型结晶 Expired - Fee Related CN1174991C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/785,623 1997-01-17
US08/785,623 US5945405A (en) 1997-01-17 1997-01-17 Crystal form O of clarithromycin

Publications (2)

Publication Number Publication Date
CN1244869A CN1244869A (zh) 2000-02-16
CN1174991C true CN1174991C (zh) 2004-11-10

Family

ID=25136084

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB971814325A Expired - Fee Related CN1174991C (zh) 1997-01-17 1997-12-19 克拉霉素的o型结晶

Country Status (18)

Country Link
US (1) US5945405A (https=)
EP (1) EP1077988A1 (https=)
JP (3) JP4058114B2 (https=)
KR (1) KR100567149B1 (https=)
CN (1) CN1174991C (https=)
AR (3) AR011077A1 (https=)
AU (1) AU735598B2 (https=)
BR (1) BR9714287A (https=)
CA (4) CA2419499A1 (https=)
CZ (1) CZ297433B6 (https=)
DE (1) DE97951771T1 (https=)
ES (1) ES2173058T1 (https=)
IL (1) IL130255A0 (https=)
NZ (1) NZ336073A (https=)
TR (1) TR199901578T2 (https=)
TW (1) TW574224B (https=)
WO (1) WO1998031699A1 (https=)
ZA (1) ZA98116B (https=)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5945405A (en) * 1997-01-17 1999-08-31 Abbott Laboratories Crystal form O of clarithromycin
KR100377159B1 (ko) * 1998-09-09 2003-08-19 한미약품공업 주식회사 잔류 용매가 없는 클라리스로마이신의 결정형 2의 제조 방법
GB9827355D0 (en) * 1998-12-11 1999-02-03 Biochemie Sa Organic compounds
KR100322313B1 (ko) * 1999-10-21 2002-02-06 민경윤 클라리스로마이신 결정형 2의 제조방법 및 이에 사용되는 클라리스로마이신 포르메이트
US6627743B1 (en) * 1999-12-03 2003-09-30 Abbott Laboratories 6-O-methylerythromycin A crystal form III
AU783055B2 (en) * 1999-12-16 2005-09-22 Teva Pharmaceutical Industries Ltd. Processes for preparing clarithromycin polymorphs and novel polymorph IV
FR2802534B1 (fr) * 1999-12-20 2002-02-01 Merial Sas Procede pour preparer et isoler la 9-deoxo-9 (z)- hydroxyiminoerythromycine a
RU2002118308A (ru) 2000-01-11 2004-02-20 Тева Фамэситикл Индастрис Лтд. (Il) Способы получения полиморфных модификаций кларитромицина
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6565882B2 (en) 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
HUP0302466A2 (hu) * 2000-02-29 2003-11-28 Teva Pharmaceutical Industries Ltd. Eljárások clarithromycin, clarithromycin intermedier, gyakorlatilag oximmentes clarithromycin és ezt tartalmazó gyógyszerkészítmény előállítására
ATE297941T1 (de) * 2000-03-15 2005-07-15 Hanmi Pharm Ind Co Ltd Verfahren zur herstellung von einer kristallinen form ii von clarythromycin
KR100367981B1 (ko) * 2000-11-23 2003-01-14 한미약품공업 주식회사 클라리스로마이신 결정형 2의 제조 방법 및 이 방법에사용되는 결정성 클라리스로마이신 메실레이트 삼수화물
BR0109544A (pt) * 2000-03-28 2003-06-10 Biochemie Gmbh Partìculas granuladas com sabor ocultado
US8980290B2 (en) 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
US7198801B2 (en) * 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
US20070225379A1 (en) * 2001-08-03 2007-09-27 Carrara Dario Norberto R Transdermal delivery of systemically active central nervous system drugs
ATE355854T1 (de) * 2000-08-03 2007-03-15 Antares Pharma Ipl Ag Neue zusammensetzung zur transdermalen und/oder transmukosalen wirkstoffanwendung mit geeignetem therapeutischen spiegel
US20040198706A1 (en) * 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US6541014B2 (en) 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
KR100408848B1 (ko) * 2001-03-12 2003-12-06 주식회사 씨트리 클래리스로마이신의 정제방법
RU2217160C2 (ru) * 2001-04-20 2003-11-27 Челябинская государственная медицинская академия Способ местного лечения урогенитального хламидиоза у женщин
JP2004537566A (ja) * 2001-08-01 2004-12-16 ブリストル−マイヤーズ　スクイブ　カンパニー 味マスキング組成物
TW200302830A (en) * 2002-01-11 2003-08-16 Chugai Pharmaceutical Co Ltd Anhydrate/hydrate of an erythromycin derivative and processes for preparing said anhydrate/hydrate
CN100427498C (zh) * 2003-03-02 2008-10-22 王凌峰 克拉霉素a型结晶
US20040185092A1 (en) * 2003-03-18 2004-09-23 Yih Ming Hsiao Pharmaceutical preparations of omeprazole and/or clarithromycin for oral use
WO2005009365A2 (en) 2003-07-21 2005-02-03 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
CA2533358C (en) 2003-07-21 2014-03-11 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
AU2004258953B2 (en) 2003-07-21 2011-02-10 Shionogi, Inc. Antibiotic product, use and formulation thereof
US8758820B2 (en) 2003-08-11 2014-06-24 Shionogi Inc. Robust pellet
JP2007502294A (ja) 2003-08-12 2007-02-08 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
US8246996B2 (en) * 2003-08-29 2012-08-21 Shionogi Inc. Antibiotic product, use and formulation thereof
JP2007513869A (ja) 2003-09-15 2007-05-31 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
DK1670433T3 (da) 2003-10-10 2012-03-12 Ferring Bv Transdermal farmaceutisk formulering til mindskelse af hudrester
US8715727B2 (en) 2004-07-02 2014-05-06 Shionogi Inc. Tablet for pulsed delivery
US20060111560A1 (en) * 2004-11-01 2006-05-25 Glenmark Pharmaceuticals Limited Process for the preparation of crystalline form II of clarithromycin
WO2006125642A1 (en) 2005-05-27 2006-11-30 Antares Pharma Ipl Ag Methods and apparatus for transdermal or transmucosal application of testosterone
CA2614412A1 (en) * 2005-07-07 2007-01-18 Elan Pharma International, Limited Nanoparticulate clarithromycin formulations
WO2007036951A2 (en) * 2005-08-31 2007-04-05 Alembic Limited Process to obtain 6-o-methylerythromycin a (clarithromycin)_form ii
US8778924B2 (en) 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
CA2646667C (en) 2006-04-21 2014-03-11 Antares Pharma Ipl Ag Methods of treating hot flashes with formulations for transdermal or transmucosal application
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
WO2008067991A2 (en) * 2006-12-08 2008-06-12 Antares Pharma Ipl Ag Skin-friendly drug complexes for transdermal administration
DE102007016367A1 (de) 2007-04-03 2008-10-09 Grünenthal GmbH Polymorph von Clarithromycin (Form V)
WO2009023191A2 (en) * 2007-08-09 2009-02-19 Teva Pharmaceutical Industries Ltd. An improved process for the preparation of clarithromycin
EP2030613A1 (en) 2007-08-17 2009-03-04 Abbott GmbH & Co. KG Preparation of compositions with essentially noncrystalline embedded macrolide antibiotics
US9119769B2 (en) 2011-12-30 2015-09-01 The Curators Of The University Of Missouri Method for transforming pharmaceutical crystal forms
CN103087130B (zh) * 2013-02-06 2015-12-23 浙江国邦药业有限公司 一种克拉霉素晶型转换方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331803A (en) 1980-06-04 1982-05-25 Taisho Pharmaceutical Co., Ltd. Novel erythromycin compounds
JPS5782400A (en) 1980-11-12 1982-05-22 Taisho Pharmaceut Co Ltd Erythromycin derivative
JPS60214796A (ja) * 1984-04-06 1985-10-28 Taisho Pharmaceut Co Ltd ６−０−メチルエリスロマイシン類の製法
JPS61103890A (ja) 1984-10-26 1986-05-22 Taisho Pharmaceut Co Ltd ６−０−メチルエリスロマイシンａ誘導体
US4670549A (en) * 1985-03-18 1987-06-02 Taisho Pharmaceutical Co., Ltd. Method for selective methylation of erythromycin a derivatives
DE3782994T2 (de) * 1986-09-18 1993-04-08 Taisho Pharma Co Ltd Erythromycin-a-derivate und verfahren zu ihrer herstellung.
JPH0755958B2 (ja) * 1986-10-03 1995-06-14 大正製薬株式会社 エリスロマイシンａ誘導体の製造方法
JP2526951B2 (ja) * 1986-12-17 1996-08-21 大正製薬株式会社 エリスロマイシンａ誘導体およびその製造方法
KR960000434B1 (ko) * 1986-12-17 1996-01-06 다이쇼 세이야꾸 가부시끼가이샤 에리스로마이신 a유도체 및 그의 제조 방법
US4808411A (en) * 1987-06-05 1989-02-28 Abbott Laboratories Antibiotic-polymer compositions
JP2751385B2 (ja) * 1988-05-19 1998-05-18 大正製薬株式会社 エリスロマイシンａオキシム及びその塩の製造方法
US5556839A (en) * 1991-04-29 1996-09-17 Eli Lilly And Company Form II Dirithromycin
US5872229A (en) 1995-11-21 1999-02-16 Abbott Laboratories Process for 6-O-alkylation of erythromycin derivatives
US5719272A (en) 1996-04-02 1998-02-17 Abbott Laboratories 2'-protected 3'-dimethylamine, 9-etheroxime erythromycin A derivatives
US5837829A (en) 1996-04-02 1998-11-17 Abbott Laboratories 9-oximesilyl erythromycin a derivatives
US5858986A (en) * 1996-07-29 1999-01-12 Abbott Laboratories Crystal form I of clarithromycin
CA2261732C (en) * 1996-07-29 2001-07-24 Abbott Laboratories Preparation of crystal form ii of clarithromycin
US5945405A (en) * 1997-01-17 1999-08-31 Abbott Laboratories Crystal form O of clarithromycin

Also Published As

Publication number Publication date
KR100567149B1 (ko) 2006-04-04
AU735598B2 (en) 2001-07-12
AR039667A2 (es) 2005-03-02
EP1077988A1 (en) 2001-02-28
JP5190350B2 (ja) 2013-04-24
CA2419499A1 (en) 1998-07-23
DE97951771T1 (de) 2004-07-08
JP2009137975A (ja) 2009-06-25
AU5532698A (en) 1998-08-07
CA2387356A1 (en) 1998-07-23
CA2277274C (en) 2003-05-27
TR199901578T2 (xx) 1999-09-21
US5945405A (en) 1999-08-31
TW574224B (en) 2004-02-01
AR011077A1 (es) 2000-08-02
ES2173058T1 (es) 2002-10-16
CA2387361C (en) 2003-05-27
JP2000509725A (ja) 2000-08-02
CA2277274A1 (en) 1998-07-23
CA2387356C (en) 2003-05-27
JP2004075689A (ja) 2004-03-11
JP4058114B2 (ja) 2008-03-05
KR20000070220A (ko) 2000-11-25
CN1244869A (zh) 2000-02-16
WO1998031699A1 (en) 1998-07-23
CZ242699A3 (cs) 1999-11-17
IL130255A0 (en) 2000-06-01
CA2387361A1 (en) 1998-07-23
BR9714287A (pt) 2000-04-18
NZ336073A (en) 2001-01-26
ZA98116B (en) 1998-07-08
CZ297433B6 (cs) 2006-12-13
AR039666A2 (es) 2005-03-02

Similar Documents

Publication Publication Date Title
CN1174991C (zh) 克拉霉素的o型结晶
CN1216892C (zh) 甲红霉素的晶形i
CN1109684C (zh) 新的化合物形态
CN1666991A (zh) 克拉霉素多晶型物的制备方法和新的多晶型物ⅳ
CN1450903A (zh) 克拉霉素多晶型物的制备方法
CN1303390A (zh) 抗病毒苯并咪唑化合物的新晶体形式
CN1914212B (zh) Gabaa激动剂的多晶型
CN1898211A (zh) 喹啉化合物的晶形及其生产方法
CN1893956A (zh) 多西环素金属络合物固体剂型
TWI530500B (zh) 非晶形ｎ-苄醯基-十字孢靈素、其製備方法及其用途
CZ20033487A3 (cs) Pediatrický přípravek gatifloxacinu
CN1324354A (zh) 玻璃状己知缓激肽拮抗剂
JP6400580B2 (ja) ３−ホルミルリファマイシンｓｖ及び３−ホルミルリファマイシンｓの３−（４−シンナミル−１−ピペラジニル）アミノ誘導体を含有する医薬製剤並びにこれらの製造方法
CN1396170A (zh) 匹伏阿德福韦的晶型
CN1049451A (zh) 抗菌素组合物
JP2007527434A (ja) 非晶質タクロリマス及びその調製
CN1789273A (zh) 一种阿奇霉素的可溶性盐及其制备方法
WO2014023027A1 (zh) 盐酸埃罗替尼多晶型物及其制备方法
CN1903869A (zh) 替比夫定的衍生物盐及其制备方法和药物应用
CN101812102B (zh) 6-o-甲基红霉素a晶型v
CN1917872A (zh) 6－11双环酮内酯衍生物的多晶型物
CZ20003709A3 (cs) Nové krystalické formy protivirivé benzimidazolové sloučeniny
CN1699384A (zh) 头孢烯类化合物磷酸酯及其制备方法和用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee

Owner name: ABBOTT PHARMACEUTICAL CO., LTD.

Free format text: FORMER NAME: ABBOTT LAB

CP01 Change in the name or title of a patent holder

Address after: Illinois State

Patentee after: Abbott GmbH. & Co. Kg

Address before: Illinois State

Patentee before: ABBOTT LABORATORIES

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20041110

Termination date: 20161219

CF01 Termination of patent right due to non-payment of annual fee